[Editors' note: For sortable and searchable tables of all 2016 US and non-US approvals and clearances, check out our Approvals Tracker.]
US FDA cleared 222 510(k)s last month. It’s a below-average amount for the US agency, but there was at least...
US Approvals Analysis: Slow 510(k) Month Includes Major Cardiac Assay Clearance
The number of 510(k) clearances in January by US FDA were lower than average, but there was at least one practice-changing advance deemed substantially equivalent last month: Roche's high-sensitivity Elecsys cardiac troponin assay. There were four original PMAs approved in January, but a lower-than-usual total of supplement approvals.
More from Approvals
More from Policy & Regulation
• By
Preparations for the reauthorization of the Medical Device User Fee Amendments for 2028-2032 are underway, with the US FDA announcing a public meeting for 4 August. After negotiations with industry and other stakeholders, a draft agreement is due to Congress by 15 January 2025.
• By
Robert Foster, HHS deputy general counsel and chief counsel for food, research and drugs, is temporarily heading the Office of Chief Counsel, but a permanent appointee is expected after Michael Stuart's confirmation as HHS general counsel.
• By
The US FDA recently published a draft guidance document for manufacturers of mesh products that are used during several types of hernia repair procedures.